Login

Forgot your password?

Register

To create an account to access your personal
My Account OR Dashboard, click REGISTER below.

Register

New Provider Enrollment

To access on-line enrollment / new provider package, click ENROLL below.

Enroll

Dr. Janet Larson, SBUMC Chief of Neonatology, Receives National Award For Most Widely Beneficial Discovery by a Physician

5/31/2007


New York Medical Society Recognizes Dr. Larsonís Fetal Gene Therapy Technology
JANET LARSON MD.

Janet E. Larson, M.D., Chief, Neonatology at Stony Brook University Medical Center, is the recipient of the 2007 Albion O. Bernstein, MD Award, presented annually by the Medical Society of the State of New York. The Society granted the 2007 award to a physician who has "the most widely beneficial discovery or developed the most useful method in medicine, surgery, or in the prevention of disease" in a 12-month period prior to November 22, 2006. The award specifically recognizes Dr. Larsonís lifelong commitment to the field of neonatology and her innovative research and development of fetal gene technologies.

"Dr. Larsonís fetal gene therapy research holds great potential for preventing congenital and debilitating lung disorders in premature infants," says Latha Chandran, M.D., M.P.H., Interim Chair, Department of Pediatrics at SBUMC, who nominated Dr. Larson for the award. "She is a leader in the area of neonatology, and her expertise and insight is invaluable in keeping Stony Brook University Medical Center at the forefront of neonatal medicine."

A nationally recognized neonatologist, Dr. Larson has cared for premature infants for more than 20 years and has investigated the use of fetal gene therapies for more than 10 years. Dr. Larson recently developed a method to transfer genes in the fetus to successfully treat congenital diaphragmatic hernia (CHD) in animal models. The clinical course of infants born with CHD is complicated by severe respiratory failure and persistent pulmonary hypertension, with a mortality rate approaching 60 percent. The disease outcome is closely linked to pulmonary hypoplasia, or underdeveloped lungs, and the gene treatment ameliorated these complications. This innovative work, published in the American Journal of Physiology (2006), showed significantly improved parameters of lung growth with the CFTR gene treatment.

Dr. Larson is the first physician from SBUMC to receive the honor from the Medical Society of the State of New York. First given in 1962, the award is endowed by the late Morris J. Bernstein in memory of his son, a physician who died in an accident while answering a hospital call in 1940. Past recipients include physicians and scientists specializing in areas such as genetics, oncology, and infectious diseases.

Board-certified in Pediatrics and Neonatology, Dr. Larson held various leadership positions in neonatal research before coming to Stony Brook in 2005. From 2003 to June 2005, she was Head of the Ochsner Childrenís Research Institute at the Ochsner Clinic Foundation in New Orleans, La. From 1991 to 2005, Dr. Larson was Director, Laboratory of Molecular Therapeutics at the Ochsner Clinic Foundation.

In 1997, Dr. Larson was named "Technologist of the Year" by the Louisiana Partnership for Technology and Innovation. In 1999, a feature in New Scientist referred to Dr. Larson as a "gene healer" for developing her method of gene therapy for the fetus. In 2002, she received a patent for genetically modified lung cells having novel morphology and immunoprotectant properties.

Dr. Larson lives in Port Jefferson with her husband and collaborator, J. Craig Cohen, Ph.D.

Make An Appointment




Important Note:

The Stony Brook Medicine University Physicians website is primarily an informational and educational resource. It should not be used in place of medical advice and recommendations you receive from your health care provider. If you have, or suspect that you have a medical problem or condition, please seek the advice of your health care provider.


Stony Brook Medicine University Physicians provides marketing advice and consultation to the clinical Faculty associated with the University Faculty Practice Corporations (UFPCs). It does not provide medical care directly or indirectly nor does it oversee, direct, manage or supervise the medical care provided by any of the individual Practices. The individual Practices are responsible for the medical care each Practice provides to its patients. Please note that the Practices listed below are separate University Faculty Practice Corporations (UFPCs).